Susie Green CEO Mermaids talking about she knows that puberty blockers are 'safe & reversable' because she follows "all the studies"
recently published long article:
'Tavistock’s Experimentation with Puberty Blockers: Scrutinizing the Evidence'
by Michael Biggs, Dept of Sociology, University of Oxford
2 March 2019
(extract)
"In 2010, Tavistock and Portman NHS Trust’s Gender Identity Development Service (GIDS) launched a trial of puberty blockers for children in their early teens with gender dysphoria. This was—and remains—an experimental treatment. These drugs, Gonadotropin-Releasing Hormone agonists (GnRHa), have not been certified as a safe or effective treatment for gender dysphoria by their manufacturers, nor by the National Institute for Clinical Excellence.
The Director of GIDS, Polly Carmichael, was keenly aware of the controversy over these drugs. ‘The question is, if you halt your own sex hormones so that your brain is not experiencing puberty, are you in some way altering the course of nature?’ (Guardian, 14 August 2008). ‘[T]he debate revolves around the reversibility of this intervention—physical and also psychological, in terms of the possible influence of sex hormones on brain and identity development’ (Carmichael and Davidson 2009). Before 2010, GIDS administered blockers to children only when they reached 16; this is the age at which young people have the presumptive capacity to consent to medical treatment.
This cautious approach was vociferously opposed by two organizations devoted to transgendering of children, Mermaids and the Gender Identity Research and Education Society. As Carmichael later recounted: ‘There was a lot of pressure coming from certain group [sic] to introduce it—families were travelling abroad because they knew it was available in Holland and America. As a service, we didn’t have the evidence one way or the other, so the best way to do it was as part of a research study’ (Vice, 16 November 2016).
Tavistock Trust announced the study on its website in April 2011. It stated that GnRHa treatment ‘is deemed reversible’. This assertion contradicted the study’s own research protocol (which I obtained under Freedom of Information from the NHS Health Research Authority). ‘It is not clear [my emphasis] what the long term effects of early suppression may be on bone development, height, sex organ development, and body shape and their reversibility if treatment is stopped during pubertal development’ (Early Pubertal Suppression in a Carefully Selected Group of Adolescents with Gender Identity Disorder, 4 November 2010, Research Ethics Committee number 10/H0713/79). A paediatrician on the study team, Russell Viner, frankly acknowledged the risks. ‘If you suppress puberty for three years the bones do not get any stronger at a time when they should be, and we really don’t know what suppressing puberty does to your brain development. We are dealing with unknowns’ (Daily Mail, 25 February 2012
Even before the final patient was enrolled, Carmichael announced success to the tabloid press. ‘Now we’ve done the study and the results thus far have been positive we’ve decided to continue with it’ (Daily Mail, 17 May 2014). In fact the decision had already been made, at least six months earlier (Daily Mail, 17 November 2013). Tavistock Trust then embraced the drug regime with enthusiasm. Three years later, GIDS (and its satellite operation in Leeds) had prescribed puberty blockers for a total of 800 adolescents under 18, including 230 children under 14 (Daily Mail, 30 July 2017). By 2018, new prescriptions were running at 300 per year (BBC News, 2 July 2018). Freedom of Information requests have failed to elicit more recent figures because GIDS does not collate basic data on this experimental treatment—and neither does the University College London Hospitals NHS Foundation Trust, which provides its endocrinology services.
Over a thousand adolescents have been given puberty blockers on the basis that the 2010–14 study yielded ‘positive’ results. Tavistock is surprisingly reticent to share these results with the scientific community. GIDS has a webpage on the evidence base for puberty blockers. It notes that ‘research evidence for the effectiveness of any particular treatment offered is still limited.’ There is no mention of its own study; it cites only research from the Netherlands. The former director of GIDS stated last year that the ‘project is ongoing and the results are yet to be published’ (De Ceglie 2018).
Diligent searching does, however, uncover some unpublished results. Most revealing is an appendix within a report to Tavistock’s Board of Directors (Carmichael 2015). It tracks the first 44 children on GnRHa, measuring changes after one year of the drug regime. The text is sometimes internally inconsistent and occasionally contradicts the tabulated figures, suggesting that it was prepared in haste. But we can summarize those changes that were reported as statistically significant (p-value < .05). Only one change was positive: ‘according to their parents, the young people experience less internalizing behavioural problems’ (as measured by the Child Behavior Checklist). There were three negative changes. ‘Natal girls showed a significant increase in behavioural and emotional problems’, according to their parents (also from the Child Behavior Checklist, contradicting the only positive result). One dimension of the Health Related Quality of Life scale, completed by parents, ‘showed a significant decrease in Physical well-being of their child’. What is most disturbing is that after a year on blockers, ‘a significant increase was found in the first item “I deliberately try to hurt or kill self”’ (in the Youth Self Report questionnaire). (continues)
concludes:
To summarize, GIDS launched a study to administer experimental drugs to children suffering from gender dysphoria. Between 2010 and 2014, puberty blockers were given to 50 children. This study yielded only one published scientific article on outcomes. It showed no evidence for the effectiveness of GnRHa: there was no statistically significant difference in psychosocial functioning between the group given blockers and the group given only psychological support. In addition, there is unpublished evidence that after a year on GnRHa children reported greater self-harm, and that girls experienced more behavioural and emotional problems and expressed greater dissatisfaction with their body—so puberty blockers exacerbated gender dysphoria. Yet the study has been used to justify rolling out this drug regime to several hundred children aged under 16. Almost five years after the last patient was enrolled in the experiment, there is no evidence to substantiate Carmichael’s claim ‘that the results thus far have been positive’."
www.transgendertrend.com/tavistock-experiment-puberty-blockers/